Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration

References

• Aänismaa P, Gatlik-Landwojtowicz E, Seelig A. (2008). P-glycoprotein senses its substrates and the lateral membrane packing density: Consequences for the catalytic cycle. Biochemistry 47:10197–10207.
   PubMedGoogle Scholar
• Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. (2010). Structure and function of the blood-brain barrier. Neurobiol Dis 37:13–25.
   PubMed Web of Science ®Google Scholar
• Azodo IA, Ehrenpreis ED. (2002). Alvimopan (Adolor/GlaxoSmithKline). Curr Opin Investig Drugs 3:1496–1501.
   PubMedGoogle Scholar
• Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, Piscitelli SC. (2005). Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: Different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 41:1787–1793.
   PubMed Web of Science ®Google Scholar
• Audus KL et al. (1986). Characterisation of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharmacol Res, 3: 81–87.
   Google Scholar
• Bauer M, Karch R, Neumann F, Abrahim A, Wagner CC, Kletter K, Müller M, Zeitlinger M, Langer O. (2009). Age dependency of cerebral P-gp function measured with ®-[11C]verapamil and PET. Eur J Clin Pharmacol 65:941–946.
   PubMed Web of Science ®Google Scholar
• Begley et al. (1996). Functional expression of P-glycoportein in an immortalised cell line of rat brain endothelial cells. J Neurochem 67: 988–995.
   PubMed Web of Science ®Google Scholar
• Brandsch M, Knutter I, Leibach F. (2004). The intestinal H+/peptide symporter PEPT1: Structure-affinity relationships. Eur J Pharmaceut Sci 21: 53–60.
   PubMed Web of Science ®Google Scholar
• Broccatelli F, Carosati E, Cruciano G, Oprea T. (2010) Transporter mediated efflux influences the CNS side effects: ABC1, from antitarget to target. Mol Inf 29: 16–26.
   PubMed Web of Science ®Google Scholar
• Bouw MR, Hammarlund-Udenaes M. (1998). Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method. Pharm Res 15:1673–1679.
   PubMedGoogle Scholar
• Chen C, Hanson E, Watson JW, Lee JS. (2003). P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31:312–318.
   PubMed Web of Science ®Google Scholar
• Callergari E et al, 2011 Br J Clin Pharmacol “Accepted article” doi: 10.1111/1365-2125.2011.03961.x
   Google Scholar
• Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675–1686.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA. (2004). XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 311:315–323.
   PubMed Web of Science ®Google Scholar
• de Lange EC, de Boer AG, Breimer DD. (2000). Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45:125–148.
   PubMed Web of Science ®Google Scholar
• de Lange EC, Danhof M. (2002). Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: Implications of the barriers between blood and brain. Clin Pharmacokinet 41:691–703.
   PubMed Web of Science ®Google Scholar
• de Miranda P, Blum MR. (1983). Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 12 Suppl B:29–37.
   PubMed Web of Science ®Google Scholar
• Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C. (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165–174.
   PubMed Web of Science ®Google Scholar
• Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. (2008). In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268–275.
   PubMed Web of Science ®Google Scholar
• Franke H, Galla H, Beuckmann CT. (2000). Primary cultures of brain microvessel endothelial cells: A valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Brain Res Protoc 5:248–256.
   PubMedGoogle Scholar
• Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M. (2009). Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233–6243.
   PubMed Web of Science ®Google Scholar
• Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. (2000). Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73–79.
   PubMed Web of Science ®Google Scholar
• Goodman and Gillman (1996) The pharmacological basis of therapeutics, Ninth edition. New York: Mc Graw Hill 1777.
   Google Scholar
• Groothuis DR, Vavra MW, Schlageter KE, Kang EW, Itskovich AC, Hertzler S, Allen CV, Lipton HL. (2007). Efflux of drugs and solutes from brain: The interactive roles of diffusional transcapillary transport, bulk flow and capillary transporters. J Cereb Blood Flow Metab 27:43–56.
   PubMedGoogle Scholar
• Hansen DK, Scott DO, Otis KW, Lunte SM. (2002). Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. J Pharm Biomed Anal 27:945–958.
   PubMed Web of Science ®Google Scholar
• Hindmarch I. (2002). CNS effects of anti-histamines: Is there a third generation of non sedative drugs? Clin Exp Aller Rev 2: 26–31.
   Google Scholar
• Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology 130:1793–1806.
   PubMed Web of Science ®Google Scholar
• Jana S, Mandlekar S, Marathe P. (2010). Prodrug design to improve pharmacokinetic and drug delivery properties: Challenges to the discovery scientists. Curr Med Chem 17:3874–3908.
   PubMed Web of Science ®Google Scholar
• Jasanoff A. (2007). MRI contrast agents for functional molecular imaging of brain activity. Curr Opin Neurobiol 17:593–600.
   PubMedGoogle Scholar
• Kalvass JC, Maurer TS, Pollack GM. (2007). Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660–666.
   PubMed Web of Science ®Google Scholar
• Kansy M, Senner F, Gubernator K. (1998). Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007–1010.
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Tomoyasu T, Tanaka M, Kanamitsu K, Sasabe H, Maeda T, Odomi M, Tamai I. (2009). Peptide derivation of poorly absorbable drug allows intestinal absorption via peptide transporter. J Pharm Sci 98:1775–1787.
   PubMed Web of Science ®Google Scholar
• Kil KE, Ding YS, Lin KS, Alexoff D, Kim SW, Shea C, Xu Y, Muench L, Fowler JS. (2007). Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 34:153–163.
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–294.
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. (2001). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today 6:150–156.
   PubMed Web of Science ®Google Scholar
• Lamberty Y, Margineanu DG, Dassesse D, Klitgaard H. (2003). H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat. Pharmacol Res 48:193–198.
   PubMed Web of Science ®Google Scholar
• Lennernas, Fager G. (1997). Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32: 403–425.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA. (2000). Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob Agents Chemother 44:2173–2175.
   PubMed Web of Science ®Google Scholar
• Levin VA. (1980). Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682–684.
   PubMed Web of Science ®Google Scholar
• Li D et al. (2003). High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38: 223–232.
   PubMed Web of Science ®Google Scholar
• Li D,Whitney-Pickett C, Umland J, Xunzhang H, Gebhard D, Lai Y, Federico III J, Davidson R, Smith R, Reyner E, Lee C, Feng B, Rotter C, Varma M, Kempshall S, Fenner K,El-Kattan A, Liston T, Troutman M. (2011) Development of a New Permeability Assay Using Low-EffluxMDCKII Cells. J Pharm Sci. DOI: 10.1002/jps.22674
   Google Scholar
• Lin JH. (2008). CSF as a surrogate for assessing CNS exposure: An industrial perspective. Curr Drug Metab 9:46–59.
   PubMed Web of Science ®Google Scholar
• Liu X, Smith B, Chen C. (2007). Progress in brain penetration Evaluation in drug discovery and development. Pers Pharmacol 325:349–356.
   Google Scholar
• Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. (2009). Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787–793.
   PubMed Web of Science ®Google Scholar
• Lipinski C, Lombardo F, Dominy B and Feeney P. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25.
   Web of Science ®Google Scholar
• Liu, S (2010) European Histamine Research Society congress. Durham, United Kingdom
   Google Scholar
• Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. (2002). Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029–1037.
   PubMed Web of Science ®Google Scholar
• Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, Polli JW. (2004). Steady-state brain concentrations of antihistamines in rats: Interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 72:92–98.
   PubMed Web of Science ®Google Scholar
• Maurer TS, Debartolo DB, Tess DA, Scott DO. (2005). Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175–181.
   PubMed Web of Science ®Google Scholar
• Miller DS. (2010). Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31:246–254.
   PubMed Web of Science ®Google Scholar
• Muzi M, Mankoff D, Link J, Shoner S, Collier A, Obradovic T, Dobson G, Shingaki T, Kungo T, Hidalgo I. (2007).Assessment of the first and second generation antihistamine brain penetration and role of P-glycoprotein. Pharmaceutical Research, 24:318–327.
   PubMedGoogle Scholar
• Neil-Dwyer G, Bartlett J, McAinsh J, Cruickshank JM. (1981). Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol 11:549–553.
   PubMed Web of Science ®Google Scholar
• Nervi P, Li-Blatter X, Aänismaa P, Seelig A. (2010). P-glycoprotein substrate transport assessed by comparing cellular and vesicular ATPase activity. Biochim Biophys Acta 1798:515–525.
   PubMed Web of Science ®Google Scholar
• Nicolazzo JA, Charman SA, Charman WN. (2006). Methods to assess drug permeability across the blood-brain barrier. J Pharm Pharmacol 58:281–293.
   PubMed Web of Science ®Google Scholar
• Nicolazzo JA, Katneni K. (2009). Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr Top Med Chem 9:130–147.
   PubMed Web of Science ®Google Scholar
• Obradovic T, Dobson GG, Shingaki T, Kungu T, Hidalgo IJ. (2007). Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 24:318–327.
   PubMed Web of Science ®Google Scholar
• Ochs HR, Greenblatt DJ, Lloyd BL, Woo E, Sonntag M, Smith TW. (1980). Entry of quinidine into cerebrospinal fluid. Am Heart J 100:341–346.
   PubMedGoogle Scholar
• O’Connor S, Labissiere G, Spencer R, Chalmers D, Menzaghi F. (2010). Safety, Pharmacokinetic and Pharmacodynamic profile of CR845, a novel peptidergic kappa opiod agonist in development for the treatment of acute pain and itch. Proceedings of the IASP Montreal.
   Google Scholar
• Oksana T et al. (2011). Physiological selectivity of the BBB microenvironment governing passive diffusion- matching with a porcine brain lipid extract artificial membrane permeability model. Phamaceut Res 28:337–363.
   PubMedGoogle Scholar
• Pardridge WM, Triguero D, Yang J, Cancilla PA. (1990). Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther 253:884–891.
   PubMed Web of Science ®Google Scholar
• Peng B, Loyd P, Shran H. (2006). Clinical pharmacokinetics of Imatinib. Clin Pharmacokinet 44:879–894.
   Google Scholar
• Peng B, Lloyd P, Schran H. (2005). Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–894.
   PubMed Web of Science ®Google Scholar
• Read KD, Braggio S. (2010). Assessing brain free fraction in early drug discovery. Expert Opin Drug Metab Toxicol 6:337–344.
   PubMed Web of Science ®Google Scholar
• Rubio-Aliaga I, Daniel H. (2002). Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol Sci 23:434–440.
   PubMed Web of Science ®Google Scholar
• Rubio-Aliaga I, Daniel H. (2008). Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 38:1022–1042.
   PubMed Web of Science ®Google Scholar
• Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD. (2005). Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503–514.
   PubMed Web of Science ®Google Scholar
• Sasongko L, Unadkat J. (2009). Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: Studies of healthy humans. Journal of Nuclear Medicine 50, 1267–1275.
   PubMedGoogle Scholar
• Schinkel AH, Wagenaar E, Mol CA, van Deemter L. (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524.
   PubMed Web of Science ®Google Scholar
• Seelig A. (2007). The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J Mol Neurosci 33:32–41.
   PubMedGoogle Scholar
• Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M,Geisslinger G, Lo¨ tsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13 651–660.
   PubMedGoogle Scholar
• Smith DA, Jones BC, Walker DK. (1996). Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16:243–266.
   PubMed Web of Science ®Google Scholar
• Song Y, Lunte CE. (1999). Comparison of calibration by delivery versus no net flux for quantitative in vivo microdialysis sampling. Analytica Chimica Acta 379, 251–262.
   Google Scholar
• Sood P, Cole S, Fraier D, Young AM. (2009). Evaluation of metaquant microdialysis for measurement of absolute concentrations of amphetamine and dopamine in brain: A viable method for assessing pharmacokinetic profile of drugs in the brain. J Neurosci Methods 185:39–44.
   PubMedGoogle Scholar
• Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. (1995). Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39:2759–2764.
   PubMed Web of Science ®Google Scholar
• Sugano K, Hamada H, Machida M, Ushio H. (2001). High throughput prediction of oral absorption: Improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J Biomol Screen 6:189–196.
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Hirabayashi H, Kimura Y, Furuta A, Amano N, and Moriwaki T (2011). Quantitative investigation of the impact of p-glycoprotein inhibition on drug transport across blood-brain barrier in rats. Drug Metab Dispos 39:8–14.
   PubMed Web of Science ®Google Scholar
• Tang C, Kuo Y, Pudvah NT, Ellis JD, Michener MS, Egbertson M, Graham SL, Cook JJ, Hochman JH, Prueksaritanont T. (2009). Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys. Biochem Pharmacol 78:642–647.
   PubMed Web of Science ®Google Scholar
• Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B, Knudsen GM, Hammarlund-Udenaes M. (2009). Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635–643.
   PubMed Web of Science ®Google Scholar
• Tang C, Kuo Y, Pudvah NT, Ellis JD, Michener MS, Egbertson M, Graham SL, Cook JJ, Hochman JH, Prueksaritanont T. (2009). Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys. Biochem Pharmacol 78:642–647.
   PubMed Web of Science ®Google Scholar
• Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K. (2004). Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 44:890–900.
   PubMed Web of Science ®Google Scholar
• Tashiro M, Kato M, Miyake M, Watanuki S, Funaki Y, Ishikawa Y, Iwata R, Yanai K. (2009). Dose dependency of brain histamine H(1) receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C]doxepin. Hum Psychopharmacol 24:540–548.
   PubMed Web of Science ®Google Scholar
• Thomas SA. (2004). Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 10:1313–1324.
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T. (2011). Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 10:1471.
   Google Scholar
• Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. (2002). Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623.
   PubMed Web of Science ®Google Scholar
• Valjakka A, Vartiainen J, Kosunen, Hippeläinen M, Pesola P, Olkkonen H, Airaksinen MM, Tuomisto L. (1996). Histaminergic modulation of neocortical spindling and slow-wave activity in freely behaving rats. J Neural Transm 103:1265–1280.
   PubMedGoogle Scholar
• Van de Waterbeemd, H., Smith, D.A. (2001) In: Pharmacokinetic Optimization in Drug Research, Testa, B., Van de Waterbeemd, H., Folkers, G., Guy, R., Eds., Weinheim, Wiley-VCH, 51–64.
   Google Scholar
• Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD. (2010a). Physicochemical space for optimum oral bioavailability: Contribution of human intestinal absorption and first-pass elimination. J Med Chem 53:1098–1108.
   PubMed Web of Science ®Google Scholar
• Varma MV, Ambler CM, Ullah M, Rotter CJ, Sun H, Litchfield J, Fenner KS, El-Kattan AF. (2010b). Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 11:730–742.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. (2002). Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623.
   PubMed Web of Science ®Google Scholar
• Williams GC, Sinko PJ. (1999). Oral absorption of the HIV protease inhibitors: A current update. Adv Drug Deliv Rev 39:211–238.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Benet L (1995) Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System. Pharm Res 22:11–23)
   Google Scholar
• Yves Lamberty, Doru Georg Margineanu, Donald Dassesse and Henrik Klitgaard. (2003) H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat. Pharmacol Res, 48:193–198.
   PubMedGoogle Scholar
• Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B. (2009). The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos 37:946–955.
   PubMed Web of Science ®Google Scholar